Fig. 6

Combination treatment of ceritinib and paclitaxel (PTX) has great inhibitory effects on AR⁻ or AR^low TNBC cells growth in vitro and in vivo. Effect of ceritinib + paclitaxel on cell viability of MDA-MB 231 Cells (A) and MDA-MB 468 cells (B). Cells were grown in DMEM with 10% FBS overnight. The cells were then treated with different dosages of ceritinib with or without 10 nM paclitaxel for 72 h. The cell viability was determined by MTT assays. MDA-MB-231 cells 231 xenograft mouse model was established in 4-5 week-old NSG female mice. Mice were assigned into four groups randomly, which were untreated control, ceritinib (25 mg/kg bodyweight) alone, PTX alone (10 mg/kg of bodyweight), and ceritinib (25 mg/kg bodyweight) + PTX (10 mg/kg of bodyweight). The tumor volume and body weight were monitored twice a week. The combination of ceritinib and PTX synergistically suppressed the MDA-MB231 xenograft tumor growth. C, experimental plan; D, Different tumors, E, tumor volume measured over a period of 50 days. F, the lung metastases were located, the quantification results were generated using Image J software in G. (sections of lungs were stained with H&E)